Pharma: Page 19
-
Permission granted by Sumitomo Pharma America
Q&A // Red Jacket winners 2023Red Jacket: Adele Gulfo, a commercialization guru
With a knack for melding science and patient-focused marketing techniques, the CEO of the biopharma commercial unit at Sumitomo Pharma America has notched blockbuster successes throughout her career.
By Karissa Waddick • Oct. 27, 2023 -
Express Scripts Holding Co.
Express Scripts sued by independent pharmacies over alleged price fixing
The Cigna-owned pharmacy benefit manager colluded with rival Prime Therapeutics to overcharge pharmacies, according to a lawsuit filed last week.
By Rebecca Pifer • Oct. 25, 2023 -
Explore the Trendline➔
Stock via Getty Images
TrendlineClinical trial diversity
As pharma wises up to the fact that the current playbook for improving clinical trial diversity has yet to make a meaningful impact, the quest is on to refine that approach.
By PharmaVoice staff -
iStock via Getty Images
Patient groups have become a powerhouse in R&D. Here’s a look at their impact.
“They have the money,” and they’re using it to influence drug development, according to the executive director of the IQVIA Institute for Human Data Science.
By Kelly Bilodeau • Oct. 25, 2023 -
iStock via Getty Images
Pfizer’s new shot approval adds to a growing vaccine prowess
Pfizer brought in a new approval for a five-in-one shot for meningococcal disease, and the company has built a sizable vaccine business over time.
By Michael Gibney • Oct. 24, 2023 -
Photo illustration: Industry Dive; Getty Images
PharmaVoice 100PharmaVoice 100s: Clinical trial gurus
Industry leaders adopting cutting-edge technologies and strategies to change the paradigm of clinical research.
By Meagan Parrish • Oct. 19, 2023 -
Permission granted by Greg Grunberg
Q&AActor and epilepsy advocate Greg Grunberg wants the world to ‘talk about it’
The actor of “Heroes” and “Star Wars: The Force Awakens” fame is starring in another role as a patient advocate for people with epilepsy.
By Michael Gibney • Oct. 19, 2023 -
Getty Images via Getty Images
For women’s health, Organon changed the financial language
Organon is partnering with governments, banks, NGOs and investors on programs to improve women’s health through results-based financing.
By Alexandra Pecci • Oct. 18, 2023 -
Stock via Getty Images
From the rainforest to Wall Street — Jaguar Health’s big play for revitalization
A pharma with a massive collection of rainforest-derived plants needs a regulatory win to overcome last year’s financial decline.
By Kelly Bilodeau • Oct. 17, 2023 -
Joe Raedle / Getty Images via Getty Images
The FDA might yank cold medicines from shelves — and that could be just the beginning
Phenylephrine’s future is up in the air with an FDA committee saying it’s not effective and a class action lawsuit alleging false advertising. What comes next could have big repercussions.
By Alexandra Pecci • Oct. 17, 2023 -
ASCO / Nick Agro
The top biopharma conferences in 2024
A few key meetings remain this year, like ESMO and ASH, while next year’s events are already being planned. Here’s a list of conferences to keep in mind.
By Ned Pagliarulo • Oct. 16, 2023 -
Getty Images via Getty Images
Has the science of anti-aging caught up with the dream of a longer life?
Billionaire investors and a new crop of longevity biotechs are betting big money on a lifespan-altering tipping point.
By Kelly Bilodeau • Oct. 16, 2023 -
Photo illustration: Industry Dive; Getty Images
PharmaVoice 100PharmaVoice 100s: Rare disease warriors
Biopharma leaders pounding away at rare diseases so patients with few other options can have healthier lives.
By Michael Gibney • Oct. 16, 2023 -
Stock via Getty Images
OpinionBranded: The trademarks pharma leaders look up to
What do brands like Patagonia, Nike and Lego have to do with pharma? Here are some of the brands industry leaders relate to most — and how they inspire work in the life sciences.
By PharmaVoice Staff • Oct. 13, 2023 -
Photo illustration: Industry Dive; Getty Images
PharmaVoice 100PharmaVoice 100s: Patient heroes
Leaders innovating new ways to incorporate patient voices in drug development and decrease barriers to access.
By Karissa Waddick • Oct. 13, 2023 -
Permission granted by Alnylam/Yvonne Greenstreet
Alnylam CEO, ‘disappointed’ with FDA’s Onpattro rejection, pivots to the future
Yvonne Greenstreet, CEO of RNAi specialist Alnylam, addressed the surprise move by regulators and the company’s new future plans.
By Michael Gibney • Oct. 12, 2023 -
Gregor Fischer/DPA/Newscom
Deep DiveA decade later, biotech’s CRISPR revolution is still going strong
Once the specialty of a few select drugmakers, CRISPR gene editing is now an essential technology for a growing group of biotechs, many led by former students of the field’s pioneering scientists.
By Gwendolyn Wu , Shaun Lucas , Julia Himmel • Oct. 12, 2023 -
Permission granted by Mike Rea.
Q&A5 minutes with — IDEA Pharma’s Mike Rea
The CEO on the secrets of innovative pharma companies, his record collection and what he’d always rather be doing.
By Meagan Parrish • Oct. 11, 2023 -
Alexander Koerner / Stringer via Getty Images
Google bets on AI in the life sciences as ‘technology for a purpose’
A life sciences exec at Google Cloud talks about the future and fears for using AI in pharma.
By Alexandra Pecci • Oct. 10, 2023 -
Photo illustration: Industry Dive; Getty Images
PharmaVoice 100PharmaVoice 100s: Tech wizards
The leaders paving the way to pharma’s future with state-of-the-art digital solutions.
By Karissa Waddick • Oct. 9, 2023 -
Stock via Getty Images
Key upcoming events for pharma execs
Trade shows and events focused on the industry’s hot-button topics, technologies and trends.
By Meagan Parrish • Oct. 6, 2023 -
Stock via Getty Images
3 marketing tips for biotechs emerging from stealth
In a crowded biotech market, here’s how your company can stand out to investors.
By Karissa Waddick • Oct. 6, 2023 -
Permission granted by Dr. Emil Kakkis.
FDA’s ‘ivory tower thinking’ ignores promising biomarkers, says a rare disease CEO
The FDA wouldn’t review a drug that was 90% effective. In rare diseases, this is too common, said Ultragenyx CEO Dr. Emil Kakkis and a leading rare disease researcher.
By Michael Gibney • Oct. 5, 2023 -
Stock via Getty Images
Drugmakers face uphill battle in Medicare negotiation suits
Judges have found fault with drug manufacturers’ First and Fifth Amendment arguments against the IRA’s drug pricing measures.
By Karissa Waddick • Oct. 4, 2023 -
Sarah Silbiger via Getty Images
5 FDA decisions to watch in the fourth quarter
The regulator is considering approval of what would be the first CRISPR medicine, as well as important clearances for Alnylam, Bristol Myers, Amgen and Pfizer.
By Ned Pagliarulo , Jonathan Gardner • Oct. 2, 2023 -
Photo illustration: Industry Dive; Getty Images
PharmaVoice 100PharmaVoice 100s: Cancer care visionaries
Leaders shaping the future of oncology and cancer care through grit and determination in the face of one of healthcare’s greatest challenges.
By Michael Gibney • Oct. 2, 2023
Previous
